Trial Condition(s):
Choroidal Neovascularization
Special Drug Use Investigation of EYLEA for Myopic choroidal neovascularization
Bayer Identifier:
17416
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
Inclusion Criteria
- Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization).
Exclusion Criteria
- Patients who have already received EYLEA treatment.
Trial Summary
Enrollment Goal
353
Trial Dates
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many Locations, Japan | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Special Drug Use Investigation of EYLEA for Myopic choroidal neovascularization
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Number of episodes of Adverse drug reaction (ADR's)Timeframe: Up to 12 months
- Number of episodes of InfectionsTimeframe: Up to 12 months
- Number of episodes of Serious Adverse Events(SAE's)Timeframe: Up to 12 months
- Number of episodes of Ocular Adverse eventsTimeframe: Up to 12 months
Secondary Outcome
- Mean changes in visual acuityTimeframe: Baseline up to 12 months
- Mean changes in retina thicknessTimeframe: Baseline up to 12 months
Additional Information
Copyright © Bayer
Powered by
